Member Info for Newuncle

Now this shows exactly why this new test is an absolute game changer

Professor Dmitry Pshezhetskiy, from UEA’s Norwich Medical School, said:

“Prostate cancer is the most common cancer in men and kills one man every 45 minutes in the UK.

“There is currently no single test for prostate cancer, but PSA blood tests are among the most used, alongside physical examinations, MRI scans and biopsies.

“However, PSA blood tests are not routinely used to screen for prostate cancer, as results can be unreliable.

“Only about a quarter of people who have a prostate biopsy due to an elevated PSA level are found to have prostate cancer.

“There has therefore been a drive to create a new blood test with greater accuracy.

“When tested in the context of screening a population at risk, the PSE test yields a rapid and minimally invasive prostate cancer diagnosis with impressive performance.

The @EpiSwitchPSE test is the shining result of a decade-long collaboration.

@OxBioDynamics

@ImperialNHS

@imperialcollege

@uniofeastanglia

UK’s leading #prostatecancer experts joined forces in the #PROSTAGRAM screening pilot, with results published in @Cancers_MPDI earlier this year.

Love the fact that so many are selling in the pennies and so many others are waiting for a cheaper entry point based on penny movements here. Obviously I don't think that way as I expect that when the next RNS drops the company value will be significantly higher and buyers will be paying huge prices to buy any. Reminds of that saying by Oscar Wilde:

What is value?

Oscar Wilde once said that "A fool is someone who knows the price of everything and the value of nothing".

Trckiy, yes typed odb way too often!!

Anyway, I don't care how the price girates up or down, I ain't selling any, happy to wait for that RNS that confirms deal inked with a major USA, UK, European distributor etc then the pennies moves here and there each day will be a thing of the past.

Slacker idiot enuf said

OB

Take a look at Myles McNulty's note published recently on Twitter that should help

#csfs

2 X £50k dt....buys?

Blimey what has become of this BB? Don't worry I won't be staying or commenting here as I prefer the solitude of my lovely peaceful CSFS thread which Jiffy stated was a red flag for him.....hmmm wonder what he thinks now eh?

Anyway enjoy your "discussions" guys

GL to you one and all

Volumes seem to be stabilising at last after two crazy 24m volume days current volume today is just 5m.

Still expect to see a few high value buys after hours here as the bigger players hoover up the traders sells here.

Once they have filled their boots I am sure the brakes will be released.

They will licence it with a big player who can do all that. Just like arm did re phone chips.

I can only assume that some are selling to bank short term profits here and are chasing the next one elsewhere as they want instant returns, hence the SP being so choppy last two days. Things will settle as the churn reduces and real investors take up the shares in larger volumes each day. Frustrating to see the market acting as it is but it's short term girations in reality. Genuine holders will be the winners here and short tem the traders will do what traders do and MMs will play their games accordingly.

Jeez how many more lies from the trolls here

Seems like we have alot of cold callers knocking at our door selling us the next big thing, trouble is they are wasting their time because we have already found it here. Don't get mugged by them

If it wasn't for cross ramping many innocent PIs would not get scammed by the pump and dump merchants infesting BBs these days!

Some pretty sad people out there trying every tactic they can to scare people out of this golden share into some other questionable stocks, wonder why?

STFU earl and go play with the traffic

Earl, give it up, you look stupid now.

As awareness of OBD, our tests and EpiSwitch® platform grows, our corporate and product branding will become increasingly important, alongside the Group's existing patents, registered trademarks and proprietary know-how. The Group's portfolio of broad, early patents extends to 18 international families of patents covering a variety of claims relating to the Group's technology and its pipeline of proprietary tests

OBD has previously highlighted its extensive pipeline of deployable molecular tests, in several disease areas, indicating that the most likely prospects for subsequent product development are in prostate and colorectal cancer screening, and canine lymphoma. This remains the case and we have been proceeding with internal and collaborative R&D work in these areas.

In prostate cancer, for example, OBD is involved in a Prostate Cancer Research-funded project to develop a test to aid detection of prostate cancer in black men, who suffer both increased prevalence of, and mortality from, this disease compared to other groups.

This work, carried out in conjunction with University of East Anglia (UEA) and Imperial College NHS Healthcare Trust builds on OBD's successful participation in the PROSTAGRAM trial. A forthcoming paper jointly written by OBD with Department of Surgery and Cancer, Imperial College, London; School of Medicine, University of East Anglia, Norwich; and King's Clinical Trials Unit, King's College London, entitled "Circulating chromosome conformation signatures significantly enhance PSA positive predicting value and overall accuracy for prostate cancer detection" sets out the exciting results of OBD's participation in the PROSTAGRAM trial.

While prostate cancer has a high lifetime prevalence (1 in 6 men), there is no generally accepted screening programme. The widely-used prostate-specific antigen (PSA) test does not have sufficient accuracy, resulting in numerous unnecessary biopsies and false reassurances. EpiSwitch® results from the PROSTAGRAM trial demonstrate that combining a standard PSA readout with non-invasive EpiSwitch biomarkers in a Prostate Screening EpiSwitch (or "PSE") test results in significantly enhanced positive predictive value (PPV) and overall accuracy for prostate cancer detection, compared to the current PSA test.

The Group will continue to prepare for the development and launch of subsequent commercial products. Whilst we will be ready to respond quickly to opportunities for commercialization in these areas, our plan is for the primary application of the Group's existing resources through 2023 to be in support of our flagship EpiSwitch® CiRT product.

"We remain confident that we will see commercial agreements with industry players in due course"